Segment Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Information

Summary of results of operations by segment

(In thousands)			Contract		Corporate		Total
Year Ended December 31, 2021	Therapeutics		Research		and Other		Company
Total revenue	$	932	$	13,447	$	(7,618)	$	6,761
Cost of revenue		—		11,885		(7,172)		4,713
Research and development		44,259		—		(446)		43,813
General and administrative		—		3,047		20,572		23,619
Revaluation of contingent consideration		24,339		—		—		24,339
Loss from operations	$	(67,666)	$	(1,485)	$	(20,572)	$	(89,723)
(In thousands)			Contract		Corporate		Total
Year Ended December 31, 2020	Therapeutics		Research		and Other		Company
Total revenue	$	696	$	13,319	$	(7,533)	$	6,482
Cost of revenue		—		12,228		(7,095)		5,133
Research and development		29,777		—		(439)		29,338
General and administrative		—		2,794		17,736		20,530
Revaluation of contingent consideration		2,393		—		—		2,393
Loss from operations	$	(31,474)	$	(1,703)	$	(17,735)	$	(50,912)
Income (loss) from discontinued operations	$	140	$	—	$	(1)	$	139
(In thousands)			Contract		Corporate		Total
Year Ended December 31, 2019	Therapeutics		Research		and Other		Company
Revenue, net	$	—	$	16,824	$	(12,597)	$	4,227
Cost of revenue		—		16,253		(12,198)		4,055
Research and development		64,564		—		(399)		64,165
Revaluation of contingent consideration		734		—		—		734
Goodwill impairment		18,504		—		—		18,504
General and administrative		620		2,738		24,469		27,827
Loss from operations	$	(84,422)	$	(2,167)	$	(24,469)	$	(111,058)
Loss from discontinued operations	$	(46,305)	$	—	$	(1,507)	$	(47,812)